The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study. by Jacq, L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/53639
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Available online http://arthritis-research.eom/content/9/4/R63
Research article
The ITGAV rs3738919-C allele is associated with rheumatoid 
arthritis in the European Caucasian population: a family-based 
study
Laurent Jacq12, Sophie G arn ier1, Philippe D ieudé13, Laetitia M ichou14, Céline P ierlo t1, Paola M igliorin i5, 
Alejandro Balsa6, René W esthovens7, Pilar Barrera8, Helena Alves9, Carlos Vaz9, Manuela Fernandes9,
Dora Pascual-Salcedo6, Stefano Bom bardieri5, Jan Dequeker7, Timothy R Radstake8, Piet Van Riel8,
Leo van de Putte8, Antonio Lopes-Vaz9, Elodie G likm ans1, Sandra Barbet1, Sandra Lasbleiz14,
Isabelle Lemaire12, Patrick Q u ille t12, Pascal H illiquin12, V itor Hugo Teixeira110, Elisabeth Petit-Teixeira1,
Hamdi M barek1, Bernard Prum11, Thomas Bardin14, François C orné lis1-2-12 
for the European Consortium  on Rheumatoid Arthritis Families
1GenHotel-EA3886, Evry-Paris VII Universities, Member of the AutoCure European Consortium, 2 rue Gaston Crémieux, 91057 Evry-Genopole 
cedex, France
2Centre Hospitalier Sud Francilien, 59 bd Henri Dunant, 91100 Corbeil-Essonnes, France
3Service de rhumatologie, Hôpital Bichat, AP-HP, 46 rue Henri Huchart, 75018 Paris, France
4Service de rhumatologie, Hôpital Lariboisière, AP-HP, 2 rue Ambroise Paré, 75010 Paris, France
5Pisa University, 561 26 Pisa, Italy
6La Paz Hospital, 28046 Madrid, Spain
7Katholieke Universiteit Leuven, BE-3000 Leuven, Belgium
8Nijmegen University, 6500HB Nijmegen, The Netherlands
9Porto San Joao Hospital, 4200 Porto, Portugal
10Faculty of Medicine, University of Coimbra, Coimbra, Portugal
"Laboratoire Statistique et Génome, Genopole, Tour Evry 2, 91000 Evry, France
12Unité de Génétique Clinique, Hôpital Lariboisière, AP-HP, 2 rue Ambroise Paré, 75010 Paris, France
Corresponding author: Laurent Jacq, laurent@polyarthrite.net
Received: 22 Feb 2007 Revisions requested: 20 Apr 2007 Revisions received: 9 May 2007 Accepted: 3 Jul 2007 Published: 3 Jul 2007
Arthritis Research & Therapy 2007, 9:R63 (doi:10.1186/ar2221)
This article is online at: http://arthritis-research.com/content/9/4/R63 
© 2007 Jacq et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Open Access
Abstract
The integrin avp3, whose av subunit is encoded by the ITGAV 
gene, plays a key role in angiogenesis. Hyperangiogenesis is 
involved in rheumatoid arthritis (RA) and the ITGAV gene is 
located in 2q31, one of the suggested RA susceptibility loci. 
Our aim was to test the ITGAV gene for association and linkage 
to RA in a family-based study from the European Caucasian 
population.
Two single nucleotide polymorphisms were genotyped by PCR- 
restriction fragment length polymorphism in 100 French 
Caucasian RA trio families (one RA patient and both parents), 
100 other French families and 265 European families available 
for replication. The genetic analyses for association and linkage 
were performed using the comparison of allelic frequencies 
(affected family-based controls), the transmission disequilibrium 
test, and the genotype relative risk.
We observed a significant RA association for the C allele of 
rs3738919 in the first sample (affected family-based controls, 
RA index cases 66.5% versus controls 56.7%; P =  0.04). The 
second sample showed the same trend, and the third sample 
again showed a significant RA association. When all sets were 
combined, the association was confirmed (affected family- 
based controls, RA index cases 64.6% versus controls 58.1%; 
P =  0.005). The rs3738919-C allele was also linked to RA 
(transmission disequilibrium test, 56.5% versus50% of 
transmission; P =  0.009) and the C-allele-containing genotype 
was more frequent in RA index cases than in controls (RA index 
cases 372 versus controls 339; P =  0.002, odds ratio =  1.94, 
95% confidence interval =  1.3-2.9).
The rs3738919-C allele of the ITGAV gene is associated with 
RA in the European Caucasian population, suggesting ITGAV 
as a new minor RA susceptibility gene.
AFBAC =  affected family-based controls; bp =  base pair; GRR =  genotype relative risk; PCR =  polymerase chain reaction; RA =  rheumatoid arthritis; 
SNP =  single nucleotide polymorphism; TDT =  transmission disequilibrium test.
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Introduction
Rheumatoid arthritis (RA) is the most common human sys­
temic autoimmune disease (0.8% prevalence in the European 
Caucasian population), affecting women preferentially [1]. The 
disease is characterized by a chronic inflammation of the syn­
ovial tissues leading to the formation of the rheumatoid pan­
nus, which erodes adjacent cartilage and bone, causing 
subsequent joint destruction. One hallmark of the pannus is 
hyperangiogenesis [2].
Previous studies have indicated that the risk of developing the 
disease in siblings of affected individuals is 2-1 7 times higher 
than in the general population, suggesting the importance of 
genetic factors [1]. Two RA genes have so far been estab­
lished and confirmed using familial material, HLA-DRB1 and 
PTPN22 [3,4], but they account only for a part of the RA 
genetic component. The dense genome scan realized in our 
laboratory suggested 19 non-HLA regions in the French Cau­
casian population [5] and one of these, 2q31, contains the 
ITG AV gene (alias CD51, av), which encodes the av subunit 
of the integrin family. This family is composed of at least 24 
heterodimeric combinations of 18 a  subunits and nine p sub­
units. These transmembranous receptors are expressed at the 
surface of numerous cells (endothelial cells, macrophages, 
monocytes, osteoclasts, platelets) and recognize the RGD 
sequence (A rg-G ly-Asp) of many ligands (such as vitronec­
tin, fibronectin, osteopontin, sialoprotein, thrombospondin, 
fibrinogen, von Willebrand factor, tenascin, agrin, matrix metal- 
loproteinases, and prothrombin) [6]. The integrins are involved 
in several functions including adhesion of activated endothelial 
cells with the extracellular matrix, proliferation, migration, and 
differentiation signals of vascular cells [6].
The avp3 integrin is well documented to play a key role in ang- 
iogenesis, and the ITGAV  knockout animal model is lethal in 
utero for 80% with a presence of large vascular anomalies 
[7,8].
Angiogenesis also plays a key role in RA when the synovial 
membrane becomes hyperplasic and destroys the cartilage.
We can observe an excess of blood cells (macrophages, T 
lymphocytes) in the synovial membrane and fluid, and some 
avp3 ligands (that is, fibrinogen or osteopontin) are abundant 
in the RA synovial fluid [7]. Moreover, some proangiogenic 
mediators (that is, vascular endothelial growth factor) are over­
expressed in RA synovial membrane and serum [9,10].
In addition, several avp3 antagonists and angiogenesis inhibi­
tors have been successfully tested on RA animal models [11­
14]. The avp3 integrin could therefore become a new thera­
peutic target in RA, and some clinical studies have already 
begun [15].
Our aim was to use RA familial material to test two intronic 
ITGAV  single nucleotide polymorphisms (SNPs) for RA asso­
ciation and linkage in the European Caucasian population.
Materials and methods
All subjects provided informed consent, and the ethics com­
mittee of Hôpital Bicêtre (Kremlin-Bicêtre, Assistance Pub- 
lique-Hôpitaux de Paris, France) approved the study. RA 
families were recruited through a national media campaign fo l­
lowed by selection of individuals who fulfilled the 1987 Amer­
ican College of Rheumatology criteria for RA according to the 
physicians in charge of the patients [16]. A rheumatologist uni­
versity fellow reviewed all clinical data.
Sample 1
Sample 1 (Table 1) constituted the DNA from 100 French 
Caucasian unrelated trio families (one RA patient and both 
parents) with the four grandparents of French Caucasian ori­
gin. Among these 100 RA patients, 87 were women; their 
mean age at disease onset was 32 years. In total, 81 patients 
were rheumatoid factor positive, 78 patients carried at least 
one HLA-DRB1 'shared epitope' susceptibility allele 
(DRB1*0101, DRB1*0102, DRB1*0401, DRB1*0404, 
DRB1*0405, DRB1*0408, DRB1*1001) [17] and 90 patients 
presented erosion.
Table 1
Characteristics of rheumatoid arthritis (RA) index cases from the investigated samples
Sample 1 (n =  100) Sample 2 (n =  100) Sample 3 (n =  265)
Females (%) 87 90 86
Mean age of disease onset (years) (±standard deviation) 32 (±10) 31 (±6) 30 (±9)
Mean disease duration (years) (±standard deviation) 18 (±7) 16 (±8) 8 (±7)
RA patients with bone erosions (%) 90 79 72
RA patients seropositive for rheumatoid factor (%) 81 76 73
RA patients carrying at least one HLA-DRB1 shared epitope allele (%) 78 80 Not available
n, number of cases.
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Sample 2
Sample 2 (Table 1) was made up of the DNA from another 100 
French Caucasian unrelated trio families w ith the same char­
acteristics as sample 1. Among these 100 RA patients, 90 
patients were women; their mean age at disease onset was 31 
years. In all, 76 patients were rheumatoid factor positive, 80 
patients carried at least one HLA-DRB1 shared epitope and 
79 patients had an erosive disease.
Sample 3
Sample 3 (Table 1) contained the DNA from 265 European 
Caucasian unrelated trio families w ith the same characteristics 
as sample 1, except for a shorter mean disease duration and a 
different ethnic origin (Caucasian families from France, Italy, 
Portugal, Spain, Belgium, and The Netherlands).
Genotyping
DNA was isolated and purified from whole blood according to 
standard protocols [18]. Two intronic SNPs were selected at 
the 5 ' and 3' ends of the gene w ith a minor allele frequency 
> 2 5 %  for European population databases. Moreover the pres­
ence of a restriction site for one of the alleles was required 
(SNP1, rs3768777 ; SNP2, rs3738919  [19,20]). G enotyping 
was performed by the PCR fo llowed by restriction fragment 
length polymorphism m ethod [21].
The designed primers were: sense, 5 '-AAG TTG C C AAC G T- 
T C C G C G T TG C A -3 ' and antisense, 5 '-G TAG TAG AAG AT- 
G G TC C TA TC C A C G -3 ' fo r S N P 1 ; and sense, 5'- 
ATTTCC AG G TG G AACTTCTTTTG G A-3' and antisense, 5'- 
TC AC AATTC AG ATTTTTG C C AC TG G -3 ' for SNP2.
PCR am plification of SNP1 and SNP2 was performed on each 
sample in a 25 |il reaction volume consisting of 10 U PCR 
buffer (Perkin Elmer, Boston, MA, USA), 1.25 mM each dNTP, 
1.25 U AmpliTaq G old DNA polymerase (Applied Biosystems, 
Foster City, CA, USA), 3 mM M gC l2, 0 .0125  nM of the two 
primers and 50 ng genom ic DNA, diluted to the final volume 
w ith H 2O on an Eppendorf therm ocycler using a hot start p ro­
cedure. The PCR program was carried out using a first dena­
turation cycle of 94 °C  for 10 minutes fo llowed by 37 cycles of 
denaturation at 94 °C  for 40  seconds, w ith an annealing tem ­
perature at 67°C  for 30 seconds fo llowed by an elongation 
step at 72°C  for 1 minute. One final cycle of the extension was 
performed at 72°C  fo r 2 minutes.
For SNP1, a 341-bp  am plified fragm ent was digested w ith 
NlaIII, generating two fragm ents when the restriction site was 
present (A allele). For SNP2, the resulting 501-bp  fragment 
was digested w ith Alul, generating three fragm ents for the C  
allele (126 bp, 161 bp and 214  bp), and tw o fragm ents for the 
A  allele (permanent restriction site allowing one to validate the 
restriction protocol; 161 bp and 340  bp). G enotypes were 
assessed blindly by two independent investigators (LJ and 
CP). CEPH contro ls (1347-02  and 884-15) and 40 patients
chosen at random were genotyped for quality control. A ll gen­
otype data will be available online [22].
Power calculation
Using the European population minor allele frequency of 29%  
and 35%  for SNP1 and SNP2, respectively, a sample size of 
100 patients and 100 controls, and the arc sinus transforma­
tion method described by Garnier and colleagues [23], we 
had 80%  power to detect an association (P  <  0.05) if the d if­
ference in allelic frequencies between patients and controls 
was at least 11%  fo r SNP1 and 12.2%  for SNP2.
Statistical analysis
Prior to association tests, we checked the H ardy-W einberg  
equilibrium in 'virtual contro ls ' (constituted by parental untrans­
mitted alleles to RA index cases).
The association and linkage between each polymorphism and 
RA was examined by three different methods: the affected 
family-based contro ls (AFBAC) method was used to compare 
transm itted and untransmitted allelic frequencies across all 
families, the transmission disequilibrium test (TDT) was used 
to de tect linkage through preferential transmission of one 
allele to the affected subjects, and the genotype relative risk 
(GRR) test was used to compare the genotypic distribution in 
patients and contro ls [24-26]. The significance of the P  value 
was assessed at 5%, leading to replication tests in sample 2 
and, in the case of relevant results, in the larger sample 3.
Results
Hardy-Weinberg equilibrium
H ardy-W einbe rg  equilibrium in the virtual contro ls was 
respected fo r SNP1 and SNP2 in sample 1 and in the replica­
tion samples (data not shown).
Test for association and linkage in sample 1
W e observed neither significant association nor linkage 
between SNP1 and RA in sample 1. For SNP2, we observed 
a significant association fo r the C  allele and a strong trend for 
a RA linkage (AFBAC, RA index cases 66.5%  versus controls 
56.7% , P =  0 .04; TDT, 59 .7%  of transmission versus 50% , P 
=  0.06) (Table 2). The GRR test showed a significant increase 
of the C /C  genotype and an excess of C-allele-containing gen­
otypes in patients (Table 3).
The linkage disequilibrium test showed a weak linkage dise­
quilibrium between SNP1 and SNP2 (D' =  0.33), and were 
thus considered independent. The results of the haplotypic 
TDT analysis showed a significant undertransmission of the 
SN P 1/S N P 2 GA haplotype (21 versus 37, P =  0.03), and a 
trend fo r an overtransmission of the tw o haplotypes containing 
the C  allele of SNP2 (data not shown).
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Table 2
Affected family-based control and transmission disequilibrium test analyses for single nucleotide polymorphism (SNP)1 and SNP2 
in sample 1 of rheumatoid arthritis trio families
Allele Affected family-based controls Transmission disequilibrium test
Rheumatoid 
arthritis cases
Controls P Transmission (%) n P
SNP1
A 0.360 0.320 0.39 54.4 90 0.39
G 0.640 0.680
SNP2
C 0.665 0.567 0.04 59.7 92 0.06
A 0.335 0.433
n, number of heterozygote parents.
Table 3
Genotype relative risk analysis for single nucleotide polymorphism (SNP)1 and SNP2 in sample 1 of rheumatoid arthritis trio 
families
Genotype Rheumatoid arthritis cases Controls P
SNP1
A/A 16 7 0.1 (global)
A/G 40 50
G/G 44 43
SNP2
C/C 45 32 0.03 (C/C versus C/A + A/A)
C/A 38 46 0.36 (C/C + C/A versus A/A)
A/A 13 18
W hen stratifying the sample for the families w ith the index pre­
senting at least one PTPN22-620W  allele or the HLA-DRB1 
allele shared epitope status, no correlation w ith the ITGAV 
genotypes could be observed (data not shown).
Test for association and linkage in sample 2
The significant association observed fo r SNP2 in sample 1 led 
to a replication test in a second set of 100 French Caucasian 
Trio families (sample 2) on the hypothesis of an association of 
the C  allele.
In this sample, we observed a trend for association and linkage 
of the C  allele w ith RA (AFBAC, RA index cases 63 .1%  versus 
contro ls 59.6% , P =  0.4; TDT, 52 .6%  of transmission, P =  
0.6) (Table 4 ). The GRR test showed a trend for an excess of 
the C-allele-containing genotype in RA index cases compared 
w ith contro ls (90 RA index cases versus 79 controls, P =  
0.09) but not for the C /C  genotype (Table 5).
The com bination of the two samples, authorized by the 
absence of any significant clinical difference between them, 
showed a marginally significant association of the C  allele 
(AFBAC, RA index cases 64 .8%  versus contro ls 58.2% , P =  
0.05; TDT, 56 .1%  of transmission, P =  0 .09) and a significant 
excess of the C-allele-containing genotype in RA index cases 
com pared w ith contro ls (173 RA index cases versus 157 con­
trols, P =  0.02).
Test for association and linkage in sample 3
The trend for association of the C  allele observed in sample 2 
was in the same direction as the significant association 
observed in sample 1, w ithout reaching statistical significance
-  notably due to a lack of power (the power to detect a s ign if­
icant association in sample 2, based on the allelic frequencies 
in sample 1, w ith P <  0.05, was only 51% ). A  larger replication 
test (265 families, sample 3) was therefore conducted on the 
hypothesis of an association of the C  allele and of the C-allele- 
containing genotype.
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Table 4
Affected family-based control and transmission disequilibrium test analyses for single nucleotide polymorphism 2 in sample 2 of 
rheumatoid arthritis trio families
Allele Affected family-based controls Transmission disequilibrium test
Rheumatoid 
arthritis cases
Controls P Transmission (%) n P
C 0.631 0.596 0.4 52.6 95 0.6
n , number of heterozygote parents.
Table 5
Genotype relative risk analysis for single nucleotide polymorphism 2 in sample 2 of rheumatoid arthritis trio families
Genotype Rheumatoid arthritis cases Controls P
C/C 33 39 0.4 (C/C versus C/A + A/A)
C/A 57 40 0.09 (C/C + C/A versus A/A)
A/A 8 19
W e observed a significant RA association and linkage fo r the 
C  allele (AFBAC, RA index cases 64 .4%  versus controls 
57.8% , P =  0.03; TDT, 57%  of transmission versus 50% , P  =  
0.04) (Table 6). This increase was supported by a significant 
increase of the C-allele-containing genotype in patients (199 
RA index cases versus 182 controls, P =  0.02) (Table 7).
Test for association and linkage in the combined 
samples 1 + 2 + 3
The combination of the three samples, authorized by the 
absence of a significant clinical difference between them, con­
firmed association and linkage fo r the C  allele (AFBAC, 64.6%  
versus 58.1% , P =  0 .005; TDT, 56 .5%  of transmission, P =
0.009) (Table 8 ). The GRR test showed an excess of the C- 
allele-containing genotype in patients (372 RA index cases 
versus 339  controls, P =  0 .002, odds ratio =  1.94, 95%  con­
fidence interval =  1 .3 -2 .9 ) (Table 9 ).
Discussion
W e studied the ITGAV gene, a good RA candidate gene for 
its function im plicated in angiogenesis, and its chromosomal 
location (in one of the 19 suggested non-HLA loci of our 
dense genome scan) [5]. W e observed a significant RA asso­
ciation for the C  allele of rs3738919  in a first sample of French 
Caucasian families, the same trend in replication sample 2, 
and again a significant association in replication sample 3 
(European Caucasian families). Finally, significant RA associa­
tion and linkage were observed when all sets were combined.
The association and linkage evidences provided by the 
present study remain nevertheless statistically modest, sug­
gesting at most a minor RA susceptib ility marker. Further s tud ­
ies in independent samples will be needed to definitively
establish association and linkage of the ITGAV rs3738919-C  
allele to RA. For the observed allelic frequencies of 64 .6%  in 
patients versus 58 .1%  in controls, a sample size of 350 fam i­
lies would be required to obtain, w ith 80%  power (P <  0.05), 
an independent replication of the association evidence 
reported here.
O nce this association had been replicated, resequencing 
would be necessary to identify exonic and prom oter SNPs to 
refine the associated haplotype.
In the same way, the chromosome 2 linkage suggestion 
observed in the genome scan of our laboratory could not be 
totally explained by the find ings of the ITGAV linkage; hence, 
w ith the overtransmission observed in the TDT, the allele shar­
ing expected for the affected sib-pair sib lings would be about 
53%  and would necessitate thousands of sibling pairs to be 
revealed. O ther RA genes in this chromosomal location and/or 
ep istatic effects could be expected to be stronger RA factors 
that remain to be discovered.
S ince the association evidence is modest, no genetic testing 
would be clinically indicated. Instead, the clinical relevance of 
the finding is likely to come through better understanding of 
the RA pathophysiology and may lead to new therapeutic 
targets.
Contrary to the result of the GRR test in sample 1, which sug­
gested a recessive effect of the ITGAV rs3738919-C  allele, 
the result of the larger com bined sample is more in favour of a 
dominant effect of this marker. This difference could be 
explained by the relatively small size of the first sample.
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Table 6
Affected family-based control and transmission disequilibrium test analyses for single nucleotide polymorphism 2 in sample 3 of 
rheumatoid arthritis trio families
Allele Affected family-based controls Transmission disequilibrium test
Rheumatoid 
arthritis cases
Controls P Transmission (%) n P
C 0.644 0.578 0.03 57 200 0.04
n, number of heterozygote parents.
Table 7
Genotype relative risk analysis for single nucleotide polymorphism 2 in sample 3 of rheumatoid arthritis trio families
Genotype Rheumatoid arthritis cases Controls P
C/C 88 76 0.2 (C/C versus C/A + A/A)
C/A 111 106 0.02 (C/C + C/A versus A/A)
A/A 22 39
Table 8
Affected family-based control and transmission disequilibrium test analyses for single nucleotide polymorphism 2 in the combined 
samples 1 +  2 +  3
Allele Affected family-based controls Transmission disequilibrium test
Rheumatoid Controls 
arthritis cases
P  Transmission (%) n P
C 0.646 0.581 0.005 56.5 387 0.009
n, number of heterozygote parents.
Table 9
Genotype relative risk analysis for single nucleotide polymorphism 2 in the combined samples 1 + 2 + 3
Genotype Rheumatoid arthritis cases Controls P
C/C
C/A
A/A
166
206
43
148
191
76
0.1 (C/C versus C/A + A/A) 
0.002 (C/C + C/A versus A/A)
Finally, regarding the key function of angiogenesis in others 
diseases, and in particular in cancers, it would be interesting 
to test the ITGAVrs3738919-C  allele in these phenotypes.
Conclusion
The present study showed a significant association and link­
age fo r the rs3738919-C  allele of the ITGAV gene w ith RA in 
the European Caucasian population, suggesting ITGAV as a 
new minor RA susceptib ility gene in this population.
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